Raymond James, Cantor bullish on uniQure following FDA update
Raymond James and Cantor both released bullish notes on uniQure (QURE) Tuesday following an update on the company's ...
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug
UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...
uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
uniQure price target raised to $44 from $26 at Leerink
Leerink raised the firm’s price target on uniQure (QURE) to $44 from $26 and keeps an Outperform rating on the shares. The firm notes the ...
UniQure shares soar on chance of speedy approval for Huntington’s therapy
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
Hosted on MSN18h
Raymond James Upgrades uniQure N.V. (QURE)
Fintel reports that on December 10, 2024, Raymond James upgraded their outlook for uniQure N.V. (NasdaqGS:QURE) from ...
pharmaphorum15h
uniQure rockets on map to market for Huntington's therapy
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
uniQure (NASDAQ:QURE) Shares Sold by Verition Fund Management LLC
Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...
BioSpace1d
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
Gene therapy developer's stock doubles after FDA grants accelerated approval
The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the ...
Why Is uniQure Stock Skyrocketing On Tuesday?
Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
Qure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.